1. Home
  2. ZLAB vs VERA Comparison

ZLAB vs VERA Comparison

Compare ZLAB & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zai Lab Limited

ZLAB

Zai Lab Limited

HOLD

Current Price

$17.76

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$49.86

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZLAB
VERA
Founded
2013
2016
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.5B
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
ZLAB
VERA
Price
$17.76
$49.86
Analyst Decision
Buy
Strong Buy
Analyst Count
6
10
Target Price
$57.22
$67.67
AVG Volume (30 Days)
806.0K
1.8M
Earning Date
11-06-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$441,629,000.00
N/A
Revenue This Year
$30.20
N/A
Revenue Next Year
$34.71
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.14
N/A
52 Week Low
$17.75
$18.53
52 Week High
$44.34
$50.09

Technical Indicators

Market Signals
Indicator
ZLAB
VERA
Relative Strength Index (RSI) 18.27 83.43
Support Level $19.40 $40.38
Resistance Level $20.22 $47.10
Average True Range (ATR) 0.52 3.35
MACD 0.09 1.34
Stochastic Oscillator 1.83 99.33

Price Performance

Historical Comparison
ZLAB
VERA

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Share on Social Networks: